But will it fix gait problems due to spasticity? You incompetently don't know that answer?
I can't for the life of me figure out what this is, Google searches provide nothing. A tiny bit more information here: FDA lists MedRhythms’ InTandem neurorehabilitation system as Class II device
More here:
Revolutionizing Stroke Recovery: An Insight into the InTandem Neurorehabilitation System
The latest here:
MedRhythms' InTandem® Rehabilitation System for Chronic Stroke Gait Impairment Receives Final Medicare Payment Determination from CMS
PORTLAND, Maine, Jan. 16, 2025 /PRNewswire/ -- MedRhythms, Inc. today announced that InTandem®, the company's flagship rehabilitation system for chronic stroke gait impairment, received a final pricing determination from the Centers for Medicare and Medicaid Services (CMS). CMS finalized the preliminary pricing determination that payments would be made on a capped rental basis, with monthly Medicare payment amounts based on the commercial pricing for InTandem.
As previously announced, CMS established a new Healthcare Common Procedure Coding System (HCPCS) code for InTandem (E3200, "Gait modulation system, rhythmic auditory stimulation, including restricted therapy software, all components and accessories, prescription only") and confirmed a Medicare benefit category determination of durable medical equipment (DME). This new pricing determination will take effect for InTandem claims with dates of service on or after April 1, 2025.
"We founded MedRhythms and developed InTandem to bring an innovative, transformational device into the lives of people living with chronic stroke walking impairments," said Brian Harris, MedRhythms' CEO and Co-Founder. "Achieving this key milestone is another crucial step in ensuring patients in need can access InTandem. We thank CMS for their consideration."
InTandem delivers individualized, progressive rhythmic auditory stimulation (RAS) therapy in the home setting, producing gait quality and speed improvements which are important to improve health outcomes and reduce the risk of adverse health events common in post-stroke patients. By leveraging wearable, clinical-grade gait sensors and a hardware control unit containing adaptive algorithms and clinically optimized music, InTandem effectively automates the key principles of RAS therapy in combination with best practices for neurorehabilitation interventions—individualization, progression, and challenge—enabling patients to access this evidence-based intervention independently at home.
Clinicians, Patients/Caregivers, and Insurers can sign up to learn more at: www.intandemrx.com
Patients/Caregivers have the ability to check their eligibility for InTandem and schedule a personal InTandem Info Call.
InTandem Indication and Intended Use
InTandem
is indicated to improve walking and ambulation in chronic stroke and is
intended to be used in the home for the physical rehabilitation of
ambulatory adults. For full prescriber information, including important
safety information and Instructions for Use (IFU), visit: www.intandemrx.com/support
About MedRhythms
MedRhythms
is pioneering the development of next-generation neurotherapeutics
designed to improve walking, mobility and related functional outcomes
via a proprietary, patented technology platform. The company's platform
combines sensors, software, and music with advanced neuroscience to
target neural circuitry. The company is developing a pipeline of
products across a range of neurological conditions, including stroke,
multiple sclerosis and Parkinson's disease. In 2021, the company
partnered with Universal Music Group and raised a Series B financing
round led by Morningside Ventures and Advantage Capital. MedRhythms is
headquartered in Portland, Maine.
For more information, visit www.medrhythms.com.
No comments:
Post a Comment